TACSTD2 and neoplasm: Datopotamab-deruxtecan is a highly potent targeted ADC which, when internalized into tumor cells expressing Trop2, results in neutralization of the target cell and also leads to killing of the cells in the nearby tumor microenvironment by the bystander-killing effect.